IRAK-targeted therapies that have matriculated to early phase trials are yielding promising
preliminary results. However, studies of IRAK kinase signaling continue to defy conventional …

Dysregulation of the innate immune system and inflammatory-related pathways has been
implicated in hematopoietic defects in the bone marrow microenvironment and associated …

Tissue inflammation is a hallmark of tumour microenvironments. In the bone marrow, tumour-
associated inflammation impacts normal niches for haematopoietic progenitor cells and …

Inflammasomes are intracellular multimeric complexes that cleave the precursors of the IL-1
family of cytokines and various proteins, found predominantly in cells of hematopoietic …

Modulating the immune system to treat diseases, including myeloid malignancies, has
resulted in the development of a multitude of novel therapeutics in recent years …

The use of the BCL2 inhibitor venetoclax has transformed the management of patients with
acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. By triggering …

Systemic autoinflammatory diseases (SAID) are conditions caused by dysregulation or
disturbance of the innate immune system, with neutrophils and macrophages the main …

The search for novel targets in chronic myeloid leukaemia (CML) is ongoing, to improve
treatment efficacy in refractory disease and increase eligibility for tyrosine kinase inhibitor …

Acute myeloid leukemia (AML) is an aggressive, clonally heterogeneous, myeloid
malignancy, with a 5-year overall survival of approximately 27%. It constitutes the most …

Chronic inflammation is a common feature of aging and numerous diseases such as
diabetes, obesity, and autoimmune syndromes and has been linked to the development of …